Corona, Magdalena
Shouval, Roni
Alarcón, Ana http://orcid.org/0000-0002-6290-1061
Flynn, Jessica
Devlin, Sean
Batlevi, Connie http://orcid.org/0000-0002-9036-9463
Mantha, Simon
Palomba, Maria Lia
Scordo, Michael
Shah, Gunjan http://orcid.org/0000-0002-9977-0456
Sauter, Craig
Perales, Miguel-Ángel http://orcid.org/0000-0002-5910-4571
Dahi, Parastoo B. http://orcid.org/0000-0002-0794-3226
Funding for this research was provided by:
consultancy to Medxus and MyBiotics
research funding to the institution from Janssen, Amgen and Beyond Spring
Article History
Received: 12 July 2022
Revised: 23 July 2022
Accepted: 26 July 2022
First Online: 21 September 2022
Competing interests
: RS- consultancy to Medxus and MyBiotics. MAP- honoraria from Abbvie, Allovir, Astellas, Bristol-Myers Squibb, Caribou Biosciences, Celgene, Equilium, Exevir, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Novartis, Nektar Therapeutics, Omeros, OrcaBio, Takeda, and VectivBio AG, Vor Biopharma. He serves on DSMBs for Cidara Therapeutics, Medigene, Sellas Life Sciences, and Servier, and the scientific advisory board of NexImmune. He has ownership interests in NexImmune and Omeros. He has received institutional research support for clinical trials from Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. He serves in a volunteer capacity as a member of the Board of Directors of the American Society for Transplantation and Cellular Therapy (ASTCT) and on the CIBMTR Cellular Immunotherapy Data Resource (CIDR) Executive Committee, and previously served on the Board of Directors of Be The Match (National Marrow Donor Program, NMDP). GS- research funding to the institution from Janssen, Amgen and Beyond Spring.